JAK-IN-20
JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo[1].
Product Specifications
CAS Number
1654776-91-6
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Neurological Disease; Inflammation/Immunology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/jak-in-20.html
Purity
99.63
Solubility
10 mM in DMSO
Smiles
O=C(NCC#N)C1=CC=C(C2=NC(NC3=CC=C(N4CCC(N5CCOCC5)CC4)C=C3)=NC=C2F)C=C1
Molecular Formula
C28H30FN7O2
Molecular Weight
515.58
References & Citations
[1]Desai J, et al. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor. Bioorg Med Chem Lett. 2022; 66:128728.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral mouse Rad52 shRNA (UAS) - Lentiviral mouseRad52 shRNA (UAS, GFP) (25)
Anti-LRRN1 Antibody Picoband®, FITC Conjugate